01166nas a2200205   4500000000100000008004100001260001200042653003000054653001500084653001600099653001800115653002600133100001300159700001300172700001400185700001200199245014500211520059000356022001400946       2021                            d  c08/202110aErythema nodosum leprosum10aapremilast10achronic ENL10arecurrent ENL10atype-2 lepra reaction1 aNarang T1 aAshraf R1 aKaushik A1 aDogra S00aApremilast in multibacillary leprosy patients with chronic and recurrent erythema nodosum leprosum: A prospective single centre pilot study.3 a<p>Recurrent or chronic erythema nodosum leprosum (ENL) is result of immunological reactions in leprosy resulting in significant morbidity and disability for the patients. It is a difficult condition to manage as patients require prolonged courses of high-dose prednisolone with risks of adverse effects (AEs), such as hypertension, diabetes or osteoporosis and steroid dependency along with immunosuppression. Steroid sparing agents like thalidomide, clofazimine, minocycline, cyclosporine, pentoxyfilline, azathioprine and methotrexate have been used with variable success rates.</p>  a1468-3083